<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554190</url>
  </required_header>
  <id_info>
    <org_study_id>ACOT 1.0</org_study_id>
    <nct_id>NCT00554190</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized, Controlled, Subject-Blinded Study to Evaluate the Safety and Effectiveness of AdvaCoat Sinus Gel Following Endoscopic Ethmoid Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carbylan Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carbylan Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of AdvaCoatÂ® sinus gel,
      a nasal/sinus dressing, for adhesion prevention following endoscopic ethmoid sinus surgery.
      Subjects were randomized to receive AdvaCoat applied to the right or left middle meatus
      tissues and Merogel applied to the middle meatus tissues on the opposite side.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic rhinosinusitis is a very common condition, affecting 35 million Americans each year.
      All paranasal sinuses need ventilation to prevent infection and inflammation. Sinus
      ventilation occurs through the ostia into the nose. When rhinosinusitis occurs, the mucous
      membranes of the sinuses become swollen, resulting in ostia closure. Functional endoscopic
      sinus surgery (FESS) is a minimally invasive surgical procedure that opens the sinus ostia.

      The most common unwanted side effect of the FESS procedure is the formation of adhesions
      (fibrous bands) in the area of surgery. These bands (adhesions) can prevent proper
      ventilation and drainage from the paranasal sinuses.

      Various hyaluronan based biomaterials are now available and in common use to provide a
      post-surgical nasal dressing which is absorbable, can prevent adhesion formation, and
      eliminate the pain and tissue abrasion caused by removal of non-absorbable nasal packing.

      AdvaCoat is a bioresorbable hyaluronan gel that conforms to mucosal surfaces and provides a
      post-surgical nasal dressing to prevent adhesion formation as tissues heal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale</measure>
    <time_frame>Post-operative through 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited and Recorded Adverse Events</measure>
    <time_frame>Post-operative through 60 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Ethmoid Sinusitis</condition>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AdvaCoat sinus gel</intervention_name>
    <description>A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Merogel Injectable</intervention_name>
    <description>Bioresorbable hyaluronic acid product</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Merogel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who:

          1. Have bilateral chronic rhinosinusitis confirmed by physical exam, clinical history,
             and prior radiography

          2. Have bilateral ethmoid sinus disease

          3. Are scheduled for bilateral anterior or total ethmoidectomy

        Exclusion Criteria:

          1. Unilateral ethmoid sinus disease

          2. Partial resection of middle turbinates, unilateral or bilateral
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew N. Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco, Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Nasal &amp; Sinus Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco, Dept of Otolaryngology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center, Department of Otolaryngology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Nasal Sinus &amp; Sleep</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <results_first_submitted>November 14, 2008</results_first_submitted>
  <results_first_submitted_qc>April 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2009</results_first_posted>
  <last_update_submitted>April 22, 2009</last_update_submitted>
  <last_update_submitted_qc>April 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marcee Maroney, V.P. Marketing and Clinical Affairs</name_title>
    <organization>Carbylan BioSurgery, Inc.</organization>
  </responsible_party>
  <keyword>rhinosinusitis, ethmoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Ethmoid Sinusitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject treatment: May 2007. Last subject treatment: December 2007.</recruitment_details>
      <pre_assignment_details>A total of 29 subjects were treated. Nineteen subjects were followed through 60 days post-treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AdvaCoat and Merogel</title>
          <description>AdvaCoat compared to Merogel Injectable. Subjects were randomized to receive AdvaCoat applied to the right or left middle meatus tissues and Merogel applied to the middle meatus tissues on the opposite side.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29">29 subjects treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19">10 subjects did not complete the Termination Study Forms</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Termination forms not completed</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AdvaCoat and Merogel Injectable</title>
          <description>AdvaCoat compared with Merogel Injectable</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale</title>
        <description>Synechia (adhesion) scale range of 0 = No visible synechia to 3 = Complete scarring between the middle turbinate and lateral nasal wall was used in the assessment.</description>
        <time_frame>Post-operative through 60 days</time_frame>
        <population>There were 19 participants that completed the final follow-up visit at 60 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Merogel Injectable</title>
            <description>Merogel Injectable compared to AdvaCoat</description>
          </group>
          <group group_id="O2">
            <title>AdvaCoat Sinus Gel</title>
            <description>AdvaCoat compared to MeroGel Injectable</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale</title>
          <description>Synechia (adhesion) scale range of 0 = No visible synechia to 3 = Complete scarring between the middle turbinate and lateral nasal wall was used in the assessment.</description>
          <population>There were 19 participants that completed the final follow-up visit at 60 days.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 (no visible synechia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (one or several visible synechia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (synechia w/ interference to sinus ventilation )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (complete scarring)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited and Recorded Adverse Events</title>
        <description>All reported events were coded to a standard set of terms using the MedDRA adverse event dictionary. Adverse events were listed and summarized.</description>
        <time_frame>Post-operative through 60 days</time_frame>
        <population>There were 19 participants who completed the 60 day follow up visits for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Merogel Injectable</title>
            <description>Merogel Injectable compared to AdvaCoat</description>
          </group>
          <group group_id="O2">
            <title>AdvaCoat Sinus Gel</title>
            <description>AdvaCoat compared to MeroGel Injectable</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited and Recorded Adverse Events</title>
          <description>All reported events were coded to a standard set of terms using the MedDRA adverse event dictionary. Adverse events were listed and summarized.</description>
          <population>There were 19 participants who completed the 60 day follow up visits for analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mucopurulent drainage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucopurulent drainage with polypoid swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcee Maroney, VP Clinical Affairs</name_or_title>
      <organization>Carbylan BioSurgery Inc.</organization>
      <phone>650 855 6774</phone>
      <email>mmaroney@carbylan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

